Clostridium difficile: new therapeutic options

Research output: Contribution to journalArticle

Abstract

Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.

Original languageEnglish (US)
Pages (from-to)455-458
Number of pages4
JournalCurrent Opinion in Pharmacology
Volume7
Issue number5
DOIs
StatePublished - Oct 2007

Fingerprint

Clostridium difficile
nitazoxanide
Metronidazole
ramoplanin
rifaximin
Diarrhea
Therapeutics
Vancomycin
Infection Control
Disease Management
Treatment Failure
Disease Outbreaks
Virulence
Anti-Bacterial Agents
Morbidity

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Clostridium difficile : new therapeutic options. / Balagopal, Ashwin; Sears, Cynthia Louise.

In: Current Opinion in Pharmacology, Vol. 7, No. 5, 10.2007, p. 455-458.

Research output: Contribution to journalArticle

@article{78eeffbd67a747d787f68626ae690c62,
title = "Clostridium difficile: new therapeutic options",
abstract = "Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.",
author = "Ashwin Balagopal and Sears, {Cynthia Louise}",
year = "2007",
month = "10",
doi = "10.1016/j.coph.2007.05.007",
language = "English (US)",
volume = "7",
pages = "455--458",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Clostridium difficile

T2 - new therapeutic options

AU - Balagopal, Ashwin

AU - Sears, Cynthia Louise

PY - 2007/10

Y1 - 2007/10

N2 - Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.

AB - Clostridium difficile disease is the major, known cause of nosocomial diarrhea and is an emerging cause of community-associated diarrhea. Recent outbreaks due to a strain of apparent increased virulence, BI/NAP1, and recognition of increasing metronidazole treatment failures as well as the morbidity associated with recurrent C. difficile disease have begun to spur studies to develop new therapies for C. difficile disease. Nitazoxanide, tolevamer, ramoplanin, and rifaximin are key agents being evaluated as new therapies for C. difficile disease. For now, vancomycin or metronidazole combined with discontinuation of antibiotics, when feasible, and expert infection control remain the mainstays of C. difficile disease management.

UR - http://www.scopus.com/inward/record.url?scp=35248851268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35248851268&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2007.05.007

DO - 10.1016/j.coph.2007.05.007

M3 - Article

C2 - 17644040

AN - SCOPUS:35248851268

VL - 7

SP - 455

EP - 458

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 5

ER -